Life Sciences Archive » March, 2008

Life Sciences - March, 2008

168 articles

• Judge Lets MS Drugmaker Off The Hook - For Now
• Cook Medical Wins Injunction Against Ex-Employees
• Bayer Appeals Yasmin Contraceptive Patent Invalidity
• Doctors Slam Cholesterol Drugs Over Safety Concerns
• FTC Puts Pressure On Health, Energy Sectors: Report
• Pfizer Loses Bid To Stay Discovery In Age Bias Suit
• Codon, Blue Heron Settle Gene-Sythesis Patent Suit
• Spanish Court Upholds Pfizer's Lipitor Patent
• Medtronic Dispute With Cordis To Stay In Texas
• U.K. Yanks Cold Medicines Over Safety Concerns
• Court Upholds Ortho-McNeil's Topamax Patent
• Kinks Persist In Class Action Fairness Act: Experts
• Hire Sheet: Law Firms Hired For Major IP Litigation
• Eisai Wins Injunction In Aricept Case
• FDA Demands Safety Plans For 25 Drugs, Biologics
• Court Throws Out Derivative Suit Against Guidant
• Courts Split Over Trademark Issues In Keyword Cases
• Shareholder Alleges Wrongdoing At NeuroMetrix
• Judge Construes Claims In Carbatrol Patent Fight
• Amgen Threatens To Sue If Roche Launches Mircera
• FDA Seeks $2.2M For Hearing Aid Violations
• HIV Drugs May Increase Risk Of Heart Attack: FDA
• Judge Rejects Arguments In Bristol-Myers Case
• FDA Says Diabetic Foot Gel Could Cause Cancer
• Abilify Off-Label Marketing Case Settled For $4M
• FDA Proposes More Stringent Rules For Some Stents
• Human Genome Hits Genentech With Patent Suit
• FDA Eyes Suicide Links With Merck's Singulair
• Amgen Ruling Will Increase Section 337 Investigations
• Invitrogen Sues GE Over Enzyme Kit Patents
• Vygon Escalates Catheter Dispute With RyMed
• SEC Probes KV Pharmaceutical Stock Options
• Lilly To Hand Over $15M To Settle Alaska Zyprexa Suit
• Court Orders Special Master In Amgen, Roche Case
• Guidant MDL Lawyers Ask Judge To Reconsider Order
• Synthes Wins Bid To Stay Clamp-Patent Feud
• Male-Enhancement Products Pose Health Risks: FDA
• Pfizer Sues To Block Generic Caduet Until 2016
• Four More Countries Recall Heparin
• Critics Say Lawyer Provision Of Vioxx Deal Is Unethical
• Novartis Escapes Some Lotensin Claims
• Pfizer's Document Bid Blocked In Celebrex Case
• Celebrity Doctor Perricone's Patents Invalidated
• AstraZeneca Gets Nod To Recruit Plaintiffs' Doctors
• Justices Reinforce Federal Preemption In Riegel
• AMS Alleges Biolitec Infringed Laser Probe Patent
• Forest Sues Sython To Protect Namenda Patent
• U.S. Targets Doctors In Kickback Scheme: Report
• 4th Circuit Rejects Wyeth Whistleblower's Appeal
• FDA Panel To Discuss New Drug Label Warnings
• AWP Case Swells As Judge Certifies Another Class
• Biovail Settles With SEC For $10M
• 3M, News Corp. Face Suit Over Ads Printed On Floors
• Neurontin Class Action To Include Generics Buyers
• China Vows Closer Oversight Of Heparin Producers
• Judge Nixes Synthes Bone-Plate Patent Suit
• Oil-For-Food, Iraq: Grist For The Anti-Corruption Mill
• Mannatech Settles Investors' Suit For $11M
• Canadian Court Upholds Lipitor Patent
• Some Employment Rights Still Foggy For Expats
• Plaintiffs Are Tripped Up by Loss Causation
• BrainLAB Hits Medtronic With $6M Bill For Legal Fees
• Judge Dismisses Eli Lilly ADHD Patent Dispute In Va.
• Judge Keeps Healthpoint Suit Alive
• Indian Court Nixes Roche's Bid To Bar Generic Tarceva
• Spiriva May Increase Stroke Risk: FDA
• FDA Warns Of High Mortality Rate For Medtronic Stent
• Ranbaxy Loses Dismissal Bid In Roche Patent Spat
• ITC Must Consider Amgen, Roche Dispute Over Mircera
• FDA Finds Impurity In Suspect Heparin Batches
• Cardica's Vessel-Graft Patent Suit Survives
• Zimmer Hit With Patent Suit Over Knee Replacement
• Judge Questions Law In Handing Wyeth Victory
• Becton Dickinson Hit With Syringe Patent Suit
• Abbott Faces Battle To Quiz Feds In AWP Suit
• Univac Antitrust Suit V. Dentsply Gets Green Light
• Grant & Eisenhofer Launches Whistleblower Group
• FDA To Look At Efficacy Of LASIK Surgery
• Suit Says Abbott Conspired To Block Generic TriCor
• Cook Wins Judgment In Heart Graft Patent Case
• CVS To Pay $36.7M To Settle Whistleblower Claims
• Amgen's Woes Worsen With Enbrel Black Box Warning
• Riegel v. Medtronic: A Win For Medical Technology
• High Court Denies Cert In Blood Storage Patent Suit
• FDA To Stop All Heparin At The Border For Testing
• FDA Reveals Plan To Open Satellite Offices In China
• Sanofi Aventis Sues Wockhardt Over Uroxatral Patent
• Nutraceutical Execs Ordered To Pay $1M
• France's Cellectis Accuses Precision Of Infringement
• Novartis Faces Suit Over Children's Cough Medicine
• U.S. Law Doesn't Trump State Claim In Paxil Suit
• Vioxx Deal May Become Model For Future Agreements
• Legislators Introduce Follow-On Biologics Bill
• Court Won't Block Generic Zyprexa In Canada
• Judge Offers Split Decision In AWP Claim Spat
• Wyeth Sues Watson Over Birth Control Patent
• Vertex Hit With Class Action Over Hepatitis Drug
• DOJ Faces Scrutiny Over Corporate Monitor Guidelines
• Germany Asks Cos. To Look For Tainted Heparin
• FDA Advises Virtual Ban On Amgen, J&J Anemia Drugs
• Compulsory License Battle Moves To Indian Court
• HIV Drug Potentially Tied To Liver Damage
• Planned Parenthood Accused Of Vast Overbilling
• FDA Regulations Expert Joins Baker Hostetler
• Rx.com Suffers Blow In Antitrust Case
• Preemption On The Mind: Recent High Court Rulings
• FDA Reappoints Former Chief Of Drug Safety Center
• FDA Issues Word Of Caution Over Tussionex
• Teva's Counterclaims Against ADHD Patent To Stand
• FDA Gives OK To Miss Some Drug Approval Deadlines
• Sanofi Sues Sandoz To Protect Ambien Patent
• Ailing Vitamin Co. Seeks Refuge In Bankruptcy
• Edwards LifeSciences Hit With $40M Verdict
• What Supplemental Briefing Bodes For Bilski
• Three Japanese Cos. Recall Heparin Products
• Gene Therapy Cos. Settle Patent Suit
• Black Box Warning Strengthened On Anemia Drugs
• Lilly's Greed Steered Course Over Zyprexa: Official
• USV Patents Method To Make Aricept Ingredient
• Thailand Does About-Face On Cancer Drug Patents
• Drug Giants Broker $125M Deal In AWP Suit
• Conn. Jumps Into Zyprexa Fray With Lawsuit
• Judge OKs Webcast Of Zyprexa Hearing
• Wyeth, Upjohn Hit With $27M In Punitive Damages
• Government Seeks To Quash Abbott Subpoenas
• One Patent Tossed, Two Upheld In Celebrex Appeal
• Innogenetics Court Likens Royalty Award To License
• Cardinal Health Plaintiffs Sent Back To Drawing Board
• GSK Probe Prompts U.K. To Boost Drug Oversight
• FDA Warns Internet Sellers Of Unapproved STD Drugs
• Timing Of Recalls Poses Challenges For Medical Cos.
• India's New Patent Regime: Impact On Global Pharmas
• Attacks On Patent Trolls Draw Concerns
• U.S. Officials Concede Vaccines Led To Disorder
• Impax Says Pfizer's Detrol Patent Suit Is Baseless
• FDA Asks GSK, Others For Data On Asthma Drugs
• Powell Gilbert Adds IP Partner
• Barr Sues Watson Over Seasonique Patent
• Pfizer Quits Bickering Over Mirapex Bellwether Trials
• Drug Safety Concerns Prompt GAO Probe Of FDA
• Biotech Co. Counsel Moves Back To Proskauer
• Dr. Reddy's Loses Bid To Invalidate Teva Patents
• Supreme Court Ruling Could Impact Aredia Case
• Business Conduct Guidelines For Health Care
• Roche Warns Of Psychotic Reactions To Tamiflu
• Medtronic Faces Stent Patent Suit From J&J, Wyeth
• Teva Sues FDA Over Delisted Risperdal Patent
• Tyco, Bondholders Spin-Off Dispute Continues
• Judge Tosses Suit Over Barr's Morning-After Pill
• Schering-Plough Loses Suit Over Laxative Marketing
• Seroquel Plaintiffs Win Bid To Quiz Doctors
• Bellwether Case Picked For Lens Solution MDL
• More FTC Officials Head Back To Private Sector
• Court Finds Listerine Class Bid Hard To Swallow
• FDA Unlikely To Curb Off-Label Marketing: Sources
• Allergan Faces DOJ Subpoena Over Botox
• High Court Recusals Questioned After Split Rulings
• Makers Of Impotence Drugs Fined $1M
• Bayer Patent Invalidated Due To Obviousness
• Plaintiffs Signing On To $5B Vioxx Deal: Merck
• Teva Faces Infringement Suits Over TriCor Patent
• Punitive Damages Possible In Wyeth Hormone Trial
• Goodwin Procter Attracts Biotech Patent Standout
• Supreme Court Deadlock Lets Rezulin Case Advance
• Judge Tosses Suit Against Anthrax Vaccine Policy
• Wyeth Wins Dimissal Of Weight-Loss Drug Suit
• Eli Lilly Gears Up For Zyprexa Showdown
• A Paradigm Shift In Obviousness For Pharma, Biotech